Cancers · 2026
Preliminary Results Regarding the Feasibility and Outcomes of MR-Linac Adaptive Stereotactic Body Radiotherapy Combined with Systemic Treatment Among Patients with Pelvic-Abdominal Recurrent or Metastatic Gynecological Malignancies: A Single-Institution Experience.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yang Xi, Zhao Shuang, Liu Zexuan, Zhang Lu, Yang Duan, Jia Shuangzheng, An Jusheng, Huang Manni
Аннотация
OBJECTIVE: Inadequate radiation delivery to recurrent pelvic and abdominal tumors is frequently attributable to the dose limitations of surrounding normal structures, particularly the intestines. Radiotherapy guided by magnetic resonance imaging (MRI) significantly enhances the accuracy of soft-tissue delineation. The purposes of this study were to demonstrate the feasibility and effectiveness of MR-Linac Adaptive stereotactic body radiotherapy in patients with pelvic-abdominal recurrent or metastatic gynecological malignancies with or without systemic therapies.
METHODS: Patients with pelvic-abdominal recurrent or metastatic gynecological malignancies are eligible for MR-Linac Adaptive stereotactic body radiotherapy. Systemic therapies, including chemotherapy, immunotherapy, and targeted therapy, are considered acceptable treatment options. The safety, tolerability, and efficacy of MR-Linac Adaptive stereotactic body radiotherapy were assessed.
RESULTS: Between October 2019 and May 2025, 15 patients were subjected to MR-Linac Adaptive stereotactic body radiotherapy. With a median follow-up period of 4.67 months (range, 0.73-20.10 months), the 6-month overall survival (OS), progression-free survival (PFS), and local control (LC) rates were 93.3%, 66.0%, and 92.3%, respectively. The 12-month OS, PFS, and LC rates were 83.8%, 37.7%, and 70.5%, respectively. The best objective response rate (ORR = CR + PR) for the irradiated lesions was 73.3% (11/15 patients). MR-Linac Adaptive stereotactic body radiotherapy led to objective responses in 73.3% (11/15) of the patients. As of the data cutoff (28 May 2025), one patient experienced dose-limiting toxicity (an enteric fistula). Another patient developed grade 4 thrombocytopenia during treatment; it was considered chemotherapy-induced.
CONCLUSIONS: These findings suggest that MR-Linac Adaptive stereotactic body radiotherapy is relatively effective and safe and can be an important treatment option for patients with pelvic-abdominal recurrent or metastatic gynecological malignancies. MR-Linac Adaptive stereotactic body radiotherapy exhibited acceptable tolerability, promising efficacy, and a favorable local control rate with regard to heavily pretreated advanced solid tumors.
METHODS: Patients with pelvic-abdominal recurrent or metastatic gynecological malignancies are eligible for MR-Linac Adaptive stereotactic body radiotherapy. Systemic therapies, including chemotherapy, immunotherapy, and targeted therapy, are considered acceptable treatment options. The safety, tolerability, and efficacy of MR-Linac Adaptive stereotactic body radiotherapy were assessed.
RESULTS: Between October 2019 and May 2025, 15 patients were subjected to MR-Linac Adaptive stereotactic body radiotherapy. With a median follow-up period of 4.67 months (range, 0.73-20.10 months), the 6-month overall survival (OS), progression-free survival (PFS), and local control (LC) rates were 93.3%, 66.0%, and 92.3%, respectively. The 12-month OS, PFS, and LC rates were 83.8%, 37.7%, and 70.5%, respectively. The best objective response rate (ORR = CR + PR) for the irradiated lesions was 73.3% (11/15 patients). MR-Linac Adaptive stereotactic body radiotherapy led to objective responses in 73.3% (11/15) of the patients. As of the data cutoff (28 May 2025), one patient experienced dose-limiting toxicity (an enteric fistula). Another patient developed grade 4 thrombocytopenia during treatment; it was considered chemotherapy-induced.
CONCLUSIONS: These findings suggest that MR-Linac Adaptive stereotactic body radiotherapy is relatively effective and safe and can be an important treatment option for patients with pelvic-abdominal recurrent or metastatic gynecological malignancies. MR-Linac Adaptive stereotactic body radiotherapy exhibited acceptable tolerability, promising efficacy, and a favorable local control rate with regard to heavily pretreated advanced solid tumors.